Incyte | INCY - Net Income


Incyte reported $303.33M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agenus USD -10.63M 74.49M Dec/2025
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amgen USD 1.82B 486M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Exelixis USD 210.47M 34.06M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Moderna USD -1.34B 517M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026